Bacteremia Clinical Trial
Official title:
Simplified Selective Digestive Tract Decontamination for the Prevention of ICU Infections in the Setting of High-level Antibiotic Resistance
A simplified graded gut decontamination protocol combined with rigorous bi-weekly screening and appropriate bacterial prophylaxis, will lead to a 25% reduction in the acquisition of blood stream infections and to a 25% reduction in lower airway colonization with multi drug resistant organisms. There will be no concomitant rise in gram-positive or fungal infection or a surgency of new resistance patterns.
Simplified Selective Digestive Tract Decontamination for the prevention of ICU infections in
a setting of high-level antibiotic resistance
Scientific Background:
Aerobic gram-negative bacilli (AGNB), Gram-positive bacteria and fungi are responsible for
hospital acquired infections. This problem is especially typical in intensive care units
(ICUs) due to the complexity of disease and wide use of invasive procedures. The common use
of empiric wide-range antibiotic therapy had lead to the development significant resistance
of these pathogens and this group of bacteria was defined as Multi-Drug Resistant Organisms
(MDRO). Among these bacteria the most important and virulent are: Carbapenem Resistant
Enterobacteriaceae (CRE), Extended Spectrum Beta Lactamases (ESBL), Methicillin Resistant
Staphylococcus Aureus (MRSA), Vancomycin Resistant Enterococci (VRE) as well as Fluconazol
resistant Candida.
The main reservoir of these organisms is the intestinal tract, which raises the possibility
that their primary eradication may lead to control of the MDRO epidemic.
Selective Digestive tract Decontamination (SDD) has been studied extensively over the last
10-15 years and there is a body of evidence that shows that this method can reduce acquired
infections, bacterial drug resistance and mortality in various ICU settings. It should be
pointed out however that many of these studies were performed in units with a low prevalence
of infection from MDROs and that they were never performed in units were CREs are endemic.
According to the described protocols, SDD was performed as a combination of an a oral
antibiotic paste - Selective Oropharyngeal Decontamination (SOD) together with enteral
medication given through a gastric feeding tube, as well as a few days of prophylactic
intra-venous treatment with an early generation cephalosporin.
This treatment method did not become a standard of care - mostly due to the concern that new
resistance will develop to the prescribed enteral antibiotics, or that there will be a rise
in the prevalence of other enteral infections as VRE, Clostridium difficile or MRSA acquired
infections. Despite evidence that during the SDD treatment period there was actually a
reduction of drug resistance, the Center for Disease Control and prevention (CDC) and the
protocols of the surviving sepsis campaign do not recommend SDD as a means of coping with
the MDRO epidemic. In published SDD protocols there was a use of wide-spectrum antibiotics
that covered the range of gram-positive, gram-negative bacteria and fungi, without
correlation to the results of primary screening in these patients. Even though this approach
did not lead to a rise in bacterial resistance, it raised enough anxiety and resistance
within the caregivers to prevent its penetration to daily use. The endemic spread of CRE
infection at Rambam Medical Center has lead us to focus on these pathogens in our SDD
program, while performing rigorous bi-weekly screening for all bacteria. We gave enteral
antibiotic treatment (Neomycin + Polymixin E) targeting AGNB, and only if the primary
screening found MRSA or Fungi, did we prescribe enteral preventive treatment against them
(Vancomycin or Nystatin). Therefore, a prospective study was performed during 2011 at Rambam
department of critical care medicine, on the influence of a simplified SDD protocol on the
acquisition of AGNB infection in the ICU. The results show a significant reduction in blood
stream infections and a change in the epidemiology of colonization of the respiratory tract
- from resistant to sensitive bacteria. There was a concomitant reduction in the use of
MDRO- targeted antibiotics.
The proposed multi-center study is based on this successful experience and will focus on the
influence of a simplified SDD protocol on colonization and infection with MDROs in israeli
ICUs where CREs are endemic.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |